Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.
2.

Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients.

Woodley DT, Cogan J, Hou Y, Lyu C, Marinkovich MP, Keene D, Chen M.

J Clin Invest. 2017 Aug 1;127(8):3028-3038. doi: 10.1172/JCI92707. Epub 2017 Jul 10.

3.

Next generation human skin constructs as advanced tools for drug development.

Abaci HE, Guo Z, Doucet Y, Jacków J, Christiano A.

Exp Biol Med (Maywood). 2017 Nov;242(17):1657-1668. doi: 10.1177/1535370217712690. Epub 2017 Jun 7. Review.

PMID:
28592171
4.

Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa.

Rashidghamat E, McGrath JA.

Intractable Rare Dis Res. 2017 Feb;6(1):6-20. doi: 10.5582/irdr.2017.01005. Review.

5.

Efficient in vivo gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse model.

Wu W, Lu Z, Li F, Wang W, Qian N, Duan J, Zhang Y, Wang F, Chen T.

Proc Natl Acad Sci U S A. 2017 Feb 14;114(7):1660-1665. doi: 10.1073/pnas.1614775114. Epub 2017 Jan 30.

6.

Lentiviral Engineered Fibroblasts Expressing Codon-Optimized COL7A1 Restore Anchoring Fibrils in RDEB.

Georgiadis C, Syed F, Petrova A, Abdul-Wahab A, Lwin SM, Farzaneh F, Chan L, Ghani S, Fleck RA, Glover L, McMillan JR, Chen M, Thrasher AJ, McGrath JA, Di WL, Qasim W.

J Invest Dermatol. 2016 Jan;136(1):284-92. doi: 10.1038/JID.2015.364.

7.

Gene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa.

Perdoni C, Osborn MJ, Tolar J.

Transl Res. 2016 Feb;168:50-58. doi: 10.1016/j.trsl.2015.05.008. Epub 2015 May 27. Review.

8.

Recessive dystrophic epidermolysis bullosa: a review of disease pathogenesis and update on future therapies.

Soro L, Bartus C, Purcell S.

J Clin Aesthet Dermatol. 2015 May;8(5):41-6. Review.

9.

Aminoglycosides restore full-length type VII collagen by overcoming premature termination codons: therapeutic implications for dystrophic epidermolysis bullosa.

Cogan J, Weinstein J, Wang X, Hou Y, Martin S, South AP, Woodley DT, Chen M.

Mol Ther. 2014 Oct;22(10):1741-52. doi: 10.1038/mt.2014.140. Epub 2014 Jul 23.

10.

Cell therapy in dermatology.

Petrof G, Abdul-Wahab A, McGrath JA.

Cold Spring Harb Perspect Med. 2014 Jun 2;4(6). pii: a015156. doi: 10.1101/cshperspect.a015156. Review.

11.

Gene therapy for skin diseases.

Gorell E, Nguyen N, Lane A, Siprashvili Z.

Cold Spring Harb Perspect Med. 2014 Apr 1;4(4):a015149. doi: 10.1101/cshperspect.a015149. Review.

12.

Generation of 3D skin equivalents fully reconstituted from human induced pluripotent stem cells (iPSCs).

Itoh M, Umegaki-Arao N, Guo Z, Liu L, Higgins CA, Christiano AM.

PLoS One. 2013 Oct 11;8(10):e77673. doi: 10.1371/journal.pone.0077673. eCollection 2013.

13.

Topical application of recombinant type VII collagen incorporates into the dermal-epidermal junction and promotes wound closure.

Wang X, Ghasri P, Amir M, Hwang B, Hou Y, Khalili M, Lin A, Keene D, Uitto J, Woodley DT, Chen M.

Mol Ther. 2013 Jul;21(7):1335-44. doi: 10.1038/mt.2013.87. Epub 2013 May 14. Erratum in: Mol Ther. 2013 Oct;21(10):1969. Khilili, Michael [corrected to Khalili, Michael].

14.

Intravenously injected recombinant human type VII collagen homes to skin wounds and restores skin integrity of dystrophic epidermolysis bullosa.

Woodley DT, Wang X, Amir M, Hwang B, Remington J, Hou Y, Uitto J, Keene D, Chen M.

J Invest Dermatol. 2013 Jul;133(7):1910-3. doi: 10.1038/jid.2013.10. Epub 2013 Jan 15. No abstract available.

15.

Molecular therapeutics for heritable skin diseases.

Uitto J.

J Invest Dermatol. 2012 Nov 15;132(E1):E29-34. doi: 10.1038/skinbio.2012.9. Review. No abstract available.

16.

Primary skin fibroblasts as a model of Parkinson's disease.

Auburger G, Klinkenberg M, Drost J, Marcus K, Morales-Gordo B, Kunz WS, Brandt U, Broccoli V, Reichmann H, Gispert S, Jendrach M.

Mol Neurobiol. 2012 Aug;46(1):20-7. doi: 10.1007/s12035-012-8245-1. Epub 2012 Feb 19. Review.

17.

Novel molecular therapies for heritable skin disorders.

Uitto J, Christiano AM, McLean WH, McGrath JA.

J Invest Dermatol. 2012 Mar;132(3 Pt 2):820-8. doi: 10.1038/jid.2011.389. Epub 2011 Dec 8. Review.

18.

Bone marrow transplantation for recessive dystrophic epidermolysis bullosa.

Wagner JE, Ishida-Yamamoto A, McGrath JA, Hordinsky M, Keene DR, Woodley DT, Chen M, Riddle MJ, Osborn MJ, Lund T, Dolan M, Blazar BR, Tolar J.

N Engl J Med. 2010 Aug 12;363(7):629-39. doi: 10.1056/NEJMoa0910501. Erratum in: N Engl J Med. 2010 Sep 30;363(14):1383. Woodley, David T [added]; Chen, Mei [added].

19.

Epidermal and dermal integration into sphere-templated porous poly(2-hydroxyethyl methacrylate) implants in mice.

Fukano Y, Usui ML, Underwood RA, Isenhath S, Marshall AJ, Hauch KD, Ratner BD, Olerud JE, Fleckman P.

J Biomed Mater Res A. 2010 Sep 15;94(4):1172-86. doi: 10.1002/jbm.a.32798.

20.

Long-term type VII collagen restoration to human epidermolysis bullosa skin tissue.

Siprashvili Z, Nguyen NT, Bezchinsky MY, Marinkovich MP, Lane AT, Khavari PA.

Hum Gene Ther. 2010 Oct;21(10):1299-310. doi: 10.1089/hum.2010.023.

Supplemental Content

Support Center